Skip to content

Efficacy and pregnancy outcome of oral metronidazole versus oral clindamycin for treating bacterial vaginosis in pregnancy at Ilorin, Nigeria. A randomized control trial.

Efficacy and pregnancy outcome of oral metronidazole versus oral clindamycin for treating bacterial vaginosis in pregnancy at Ilorin, Nigeria. A randomized control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202304665943139
Enrollment
500
Registered
2023-04-28
Start date
2023-04-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Study group

Sponsors

self funded
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: • All consenting pregnant women attending antenatal clinic at the study site between 20 and 26weeks of gestation. • Single live intrauterine foetus • Desire to deliver at the study site.

Exclusion criteria

Exclusion criteria: • Use of antibiotics in the preceding two weeks before recruitment into the study. • Allergy to metronidazole or clindamycin • Previous history of preterm birth • Previous and present history of preterm premature rupture of membrane (SPROM) • Patient on cerclage. • Chronic medical disorders that can predispose to preterm birth such as diabetes mellitus, lentiviral infection and hypertensive disorders in pregnancy. • Multiple pregnancy

Design outcomes

Primary

MeasureTime frame
The primary outcome will be the cure rate following laboratory diagnosis and administration of antibiotic to treat bacterial vaginosis;The primary outcome will be the cure rate following laboratory diagnosis and administration of antibiotic to treat BV.

Secondary

MeasureTime frame
The secondary outcome measures will be measured by pregnancy outcomes such as gestational age at delivery, birth weight, neonatal APGAR scores at first and fifth minutes of life, neonatal intensive care unit admission and the presence of any side effects of the drug such nausea, vomiting and diarrhoea.

Countries

Nigeria

Contacts

Public Contactganiyat akera adegboyega

registrar

ghanak622@gmail.com08157697396

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026